DVHGF.US Devonian Health Group Inc.

Healthcare Biotechnology USA Stocks
4.80 USD
Close of Nov 14, 2026
4.27 10.65
Market cap
USD 13.3M
P/E
-
P/B
2.73x
ROE
-109.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Apr 2026.

Is DVHGF.US undervalued?

Graham number

The Graham number of Devonian Health Group Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Devonian Health Group Inc. fundamental analysis

No fundamental analysis for Devonian Health Group Inc. yet.

Devonian Health Group Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Devonian Health Group Inc.

Devonian Health Group Inc. operates as a clinical stage biopharmaceutical corporation with novel therapeutic approaches targeting unmet medical needs in Canada and Internationally. It engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS assoc…

Full company profile